Coherus Oncology, Inc. (CHRS) vs PepGen Inc. (PEPG)
A side-by-side comparison of Coherus Oncology, Inc. and PepGen Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CHRS
Coherus Oncology, Inc.
$1.06HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT
PEPG
PepGen Inc.
$2.35HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT
Total return — CHRS vs PEPG
growth of $100 · dividends reinvested · last 4yCHRS -86.7% (-39.6%/yr)PEPG -81.7% (-34.6%/yr)PEPG compounded faster over this window
CHRS PEPG
CHRS vs PEPG: by the numbers
- •CHRS is the larger company ($163M vs $162M market cap).
- •Both run net losses; PEPG's is the smaller (0.00% vs -257.10% net margin).
Metrics side by side
Valuation
| Metric | CHRS | PEPG |
|---|---|---|
| P/S ratio | 3.20 | N/A |
| P/B ratio | 2.68 | 1.36 |
Profitability
| Metric | CHRS | PEPG |
|---|---|---|
| Gross margin | 63.55% | 0.00% |
| Operating margin | -425.72% | 0.00% |
| Net margin | -257.10% | 0.00% |
| ROE | -215.26% | -60.19% |
| ROIC | -135.38% | -57.59% |
Growth (annualized)
| Metric | CHRS | PEPG |
|---|---|---|
| Revenue CAGR (5Y) | -33.60% | N/A |
| Total return CAGR (5Y) | -41.38% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.